Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Saeed Tavazoie, Ph.D.

Co-founder & Board Director

Saeed is a Professor in the Department of Biochemistry and Molecular Biophysics at Columbia University. He received his graduate training at Harvard Medical School where he developed the very first computational methods for discovering regulatory networks from large scale genomic data. He has made fundamental contributions to the field of systems biology, including methods for discovering and validating regulatory perturbations in cancer. A major focus of his laboratory is to reveal how transcription factors, microRNAs, and RNA-binding proteins orchestrate precise patterns of gene expression sub-serving pathological states. Among his many awards are the NSF CAREER and the NIH Director’s Pioneer Awards.